Quick Answer
Axsome Therapeutics, Inc. reported Stockholders Equity of $88.30 million for fiscal year 2025.
Axsome Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $88.30M | +54.9% |
| 2024 | $57.02M | -70.1% |
| 2023 | $190.98M | +74.3% |
| 2022 | $109.56M | +600.9% |
| 2021 | $15.63M | -86.3% |
| 2020 | $113.79M | -36.3% |
| 2019 | $178.72M | +18955.2% |
| 2018 | $937.9K | -94.4% |
| 2017 | $16.72M | -22.5% |
| 2016 | $21.57M | -53.6% |
| 2015 | $46.44M | +1550.2% |
| 2014 | -$3.20M | -57.9% |
| 2013 | -$2.03M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $73.73M | -20.6% | +0.9% |
| June 30, 2025 | $73.08M | -29.0% | +37.3% |
| March 31, 2025 | $53.20M | -63.1% | -6.7% |
| December 31, 2024 | $57.02M | -70.1% | -38.6% |
| September 30, 2024 | $92.90M | -65.5% | -9.7% |
| June 30, 2024 | $102.85M | -63.1% | -28.6% |
| March 31, 2024 | $144.04M | +28.8% | -24.6% |
| December 31, 2023 | $190.98M | +74.3% | -29.1% |
- Axsome Therapeutics, Inc. showed an increase of +54.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2013–2025 period, Axsome Therapeutics, Inc.’s stockholders equity has grown by 4454.2% (from -$2.03 million to $88.30 million).
- The most recent figure is from Axsome Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: